Riskpilot← Back to searchSign inGet full accessLinick Medica AB
ABActiveOrg 5566499256Högalidsgatan 19Medical specialists activities · NACE 8622Est. 20031 employees
Revenue 2024
SEK 3,3M
-12% vs 2023
EBITDA margin
44.7%
+3% vs 2023
Equity ratio
56.4%
Financial strength
Net profit 2024
SEK 860K
+11% vs 2023
| Revenue | SEK 3,3M | -12% |
| EBITDA | SEK 1,5M | +3% |
| Net profit | SEK 860K | +11% |
| Total assets | SEK 6,2M | +25% |
| Equity | SEK 3,5M | +23% |
| Employees | 1 | — |
Legal name
Linick Medica AB
Org number
5566499256
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
27 oktober 2003
Share capital
SEK 100 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva sjukvård inom öron-näsa-hals samt käkkirurgi och därmed förenlig verksahmet.
Address
Högalidsgatan 19
Email
jahan.linkoping@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 2 464 | 3 866 | 3 689 | 3 786 | 3 319 |
| Staff expenses | — | — | — | −278 | −338 |
| EBITDA | 565 | 1 047 | 1 190 | 1 439 | 1 482 |
| Depreciation & amort. | −119 | −137 | −143 | −143 | −62 |
| EBIT | 446 | 910 | 1 047 | 1 296 | 1 420 |
| Net financials | −19 | −18 | −17 | −19 | −9 |
| Profit before tax | 268 | 818 | 913 | 989 | 1 107 |
| Tax | −62 | −175 | −193 | −213 | −247 |
| Net profit | 206 | 643 | 720 | 776 | 860 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 2 872 | 3 439 | 3 832 | 4 997 | 6 234 |
| Equity | 1 224 | 1 680 | 2 276 | 2 856 | 3 516 |
| Long-term debt | 360 | 256 | 152 | 35 | 399 |
| Short-term debt | 472 | 613 | 396 | 810 | 719 |
| Total debt | 832 | 869 | 548 | 845 | 1 119 |
EBITDA margin
44.7%
This company
15.8%
Market median
+183% vs market
20202024
Equity ratio
56.4%
This company
38.2%
Market median
+48% vs market
20202024
Return on equity
24.4%
This company
18.4%
Market median
+33% vs market
20202024
Net profit margin
25.9%
This company
8.1%
Market median
+220% vs market
20202024
Asset turnover
0.53×
This company
1.12×
Market median
-53% vs market
20202024
Debt / equity
0.77×
This company
0.62×
Market median
+24% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CG | Audit | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Linick Medica AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Carl-Johan Georg Sandberg | Audit | 0 companies |
| Lina Sara Abtahi | Deputy Board Member | 0 companies |
| Jahanmehr Abtahi | Board of Directors | 0 companies |